JUN and metabolic dysfunction-associated steatotic liver disease: The network analysis revealed that the primary active components of HQGG (quercetin, kaempferol, formononetin, puerarin, etc.)might regulate PTGS2, AKT1, MAPK1, JUN, PPARG, and other targets, and also act on various signaling pathways such as those related to the AGE‐RAGE signaling pathway in diabetic complications, lipid and atherosclerosis, fluid shear stress and atherosclerosis, NAFLD, and the IL‐17 signaling pathway, thereby playing an important role in treating MAFLD.